Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

Accrued expenses 7,675 6,182 Deferred rent 80 124 Deferred revenue 985 1,857 -------- -------- Total current liabilities 18,786 13,323 Deferred rent - 80 Deferred revenue 2,956 3,869 Long-term debt, net 12,096 16,523 -------- -------- Total liabilities 33,838 33,795 -------- -------- Commitments and contingencies STOCKHOLDERS' EQUITY: Common stock, $0.001 par value, 100,000,000 shares authorized, 28,268,004 and 23,340,498 shares issued and outstanding at September 30, 2009, and September 30, 2008, respectively 28 23 Warrants to purchase 127,248 and 116,183 shares of common stock for $12.05 per share as of September 30, 2009 and 2008, respectively 1,230 1,140 Additional paid-in capital 195,025 145,819 Accumulated other comprehensive (loss) income - (3) Accumulated deficit (167,385) (111,792) -------- -------- Total stockholders' equity 28,898 35,187 -------- -------- Total $62,736 $68,982 ======== ========

SOURCE Pharmasset, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "12th Annual Report ... report to their offering. The ... Manufacturing Capacity and Production is the most recent ... current and projected future capacity and production. The ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
(Date:8/28/2015)... The scientific team of a new ... the leading academics in the field of aging Prof. ... life extension for model animals - 10 fold for nematodes) ... age-related diseases, primarily, around the stability and stress resistance of ... as "Stability analysis of a model gene network links aging, ...
Breaking Medicine Technology:12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Quetiapine Market Investigation Report 2010-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3
... Philips recently recalled specific lots of infant ... H Set Microstream carbon dioxide (CO2) sampling lines ... Lot CodesM1923A , Philips Filterline H Set ... Set Infant/Neo , M8409P10Philips initiated the recall in ...
... Technologies Corp. (NASDAQ: BSTC ), a ... today provided an update on the launch progress ... reported by BioSpecifics, strategic partner, Auxilium Pharmaceuticals, Inc. ... Pfizer, Inc. (Pfizer) in 7 European countries: the ...
Cached Medicine Technology:Recall of Infant and Neonatal-Sized FilterLine H Set and VitaLine H Set Sampling Lines 2BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU 2BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU 3
(Date:8/28/2015)... ... 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients ... pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. , Dr. ... and then went on to earn his title of Doctor of Chiropractic from the ...
(Date:8/28/2015)... ... 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, was treated ... a good cause. In its second year, the “Music With A Mission” benefit concert ... The “Mission” of “Music With A Mission” is to raise money to help fund ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The newest ... not be available for general use any time soon, according to educational website Surviving ... biologic therapy that received orphan drug designation for mesothelioma last week from the FDA, ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... External Counterpulsation, ... Heart Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines with a ... Fit Clinic has been in business since 2007 helping people prevent and reverse ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked ... an exclusive ranking of the nation’s fastest-growing private companies. The list was unveiled online ... growth of 85% over the last three years, PREVENT ranks higher on the list ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... "Aloha Spirit" goes worldwide: every online purchase of new Maui Jim ... eye disease ... , , LAHAINA, Hawaii, June 24 ... new pair of Maui Jim sunglasses from http://www.mauijim.com ... of new Maui Jim,s to Unite for Sight, the preeminent non-profit ...
... Whole Body Radiosurgery to Nashville , , SUNNYVALE, ... ), a global leader in the field of radiosurgery, announced ... at a Hospital Corporation of America (HCA) facility. The installation ... Medical Center in Nashville, Tenn. , , "The ...
... of Phosphatidylserine-Targeting Antibodies to Image Solid Tumors and Other Malignancies ... Showing Utility of PS-Targeting Antibodies for the Molecular Imaging of ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... vascular imaging applications for phosphatidylserine (PS)-targeting antibodies. The patent ...
... Novasys Medical, Inc., a developer of innovative therapies in ... 2009, First Coast Service Options, Inc. ("First Coast"), a ... in Florida, Puerto Rico and the U.S. Virgin Islands, ... stress urinary incontinence (SUI) from its noncovered services list ...
... of the Six Physicians Honored by Surescripts Use Allscripts ... CHICAGO, June 24 Allscripts (Nasdaq: MDRX ... accounted for half of the "E-Prescriber of the Year" ... that organization,s Fourth Annual Safe-Rx(TM) Awards. Safe-Rx is an ...
... , SHENZHEN, China, June 24 /PRNewswire-FirstCall/ - Hard to ... that the Company is in the process of recovering ... financial benefit to the Company. , The Company retained ... certain intellectual property, which the current management, preferred shareholder ...
Cached Medicine News:Health News:Maui Jim Teams With Unite for Sight in New 'Buy One, Give One' Program to Improve Eye Health Amongst the World's Most Needy 2Health News:Maui Jim Teams With Unite for Sight in New 'Buy One, Give One' Program to Improve Eye Health Amongst the World's Most Needy 3Health News:10th CyberKnife System Installed at an HCA Hospital 2Health News:10th CyberKnife System Installed at an HCA Hospital 3Health News:10th CyberKnife System Installed at an HCA Hospital 4Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 4Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 2Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 3Health News:Allscripts Clients Win Half of National 'E-Prescriber of the Year' Awards 2Health News:Allscripts Clients Win Half of National 'E-Prescriber of the Year' Awards 3Health News:Allscripts Clients Win Half of National 'E-Prescriber of the Year' Awards 4Health News:Allscripts Clients Win Half of National 'E-Prescriber of the Year' Awards 5Health News:Hard To Treat Diseases (HTDS.PK) To Regain Intellectual Property (IP) Ownership 2Health News:Hard To Treat Diseases (HTDS.PK) To Regain Intellectual Property (IP) Ownership 3
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
RIA kit for the quantitative determination of autoantibodies to thyroglobulin in serum....
For the quantitative determination of Estradiol (E2) concentration in human serum or plasma....
... Estradiol (E2) is the most potent, naturally ... produced by the ovary [1]. In the ... and from estrone, a less potent estrogen ... interconverted in many body tissues. In men, ...
Medicine Products: